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Background: Biologic agents are routinely used in the treatment of severe psoriasis. The evaluation of 
treatment response is mainly based on the physician’s global clinical assessment.
Objective: To investigate whether dermoscopy might enhance the assessment of response of psoriasis 
to treatment with biologic agents.
Methods: Patients with severe psoriasis scheduled to receive a biologic agent were enrolled in the 
study. A target lesion from each patient was clinically and dermoscopically documented at baseline 
and after one, two and six months. The clinical response was evaluated by the recruiting clinicians at 
all visits, while dermoscopic images were evaluated by two independent investigators, blinded to the 
clinical information. Chi Square test was used for cross-tabulation comparisons, while odds ratios, 
95% confidence intervals and p values were calculated using univariate logistic regression.
Results: Overall, there was a significant correlation between clinical response and vessel distribution 
at all time points: a regular vessel distribution correlated with no response, a clustered distribution 
with partial response, and the dermoscopic absence of vessels with complete response. The presence 
of dermoscopic hemorrhagic dots was a potent predictor of favorable clinical response at the subse-
quent visit at all time points. Among lesions initially clinically responding and later recurring, 87.5% 
displayed dermoscopic dotted vessels despite the macroscopic remission.
Conclusion: Dermoscopy might be a useful additional tool for evaluating the response of psoriatic pa-
tients to biologic agents. Hemorrhagic dots represent an early predictor of clinical response, while the 
persistence or reappearance of dotted vessels might predict clinical persistence or recurrence, respectively.
ABSTRACT
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agent of their choice based on standard clinical procedures, 
with the choice of drug not being at all influenced by the 
present study.
A target lesion located on the trunk or the extremities was 
selected from each patient to be documented and monitored. 
The target lesion could be of any size and lack significant 
hyperkeratosis. In case all the psoriatic lesions were highly 
hyperkeratotic, a keratolytic cream, without steroid, was 
applied one week prior to the enrollment. Exclusion criteria 
were: the previous application of topical treatment, with the 
exception of the keratolytic cream mentioned above, on the 
selected lesion or the administration of any systemic agent 
within the previous three months of enrollment.
A clinical and dermoscopic image was captured from 
the target lesion at baseline visit (T0). Follow up visits were 
scheduled after one month (T1), two months (T2) and six 
months (T3). During all the follow up visits, a clinical and 
dermoscopic image of the target lesion was captured. All 
dermoscopic images were captured with polarized light using 
Dermlite Photo System (3Gen, San Juan Capistrano, CA, 
USA). Minimal pressure was applied in order to preserve ves-
sel morphology and to facilitate their visualization.
The clinical response of the target lesion was evaluated 
by the recruiting clinicians in all follow up visits (T1, T2, 
T3) as: not responding, partially responding or completely 
remitted, always as compared to the baseline visit. This means 
that there was the possibility for a lesion to be evaluated as 
completely responding at a certain time point and partially 
(or not at all) responding at a later point (recurrence).
The dermoscopic images were evaluated by two inde-
pendent investigators, blinded to clinical information. In 
case of disagreement, a third investigator was involved. The 
dermoscopic variables were selected on the basis of available 
literature on dermoscopy of psoriasis and our initial obser-
vation that hemorrhagic dots represent a common finding 
in psoriatic lesions under treatment with biologic agents [6, 
10-12]. An example highlighting the difference between hem-
orrhagic dots and the typical red dots of psoriasis is shown 
in Figure 1 and several additional examples of hemorrhagic 
dots in Figure 2.
During the follow-up visits, the distribution of red dot 
vessels was assessed as regular (i.e., equally covering all the 
surface of the lesion), clustered (i.e., grouped arrangement 
of dotted vessels in some areas of the lesion, while other 
areas displayed no vessels), or minimal, when only a few 
(<10) red dots could be seen either isolated or scattered on 
the lesion surface. White scales are also known as a frequent 
dermoscopic finding in psoriasis. However, the presence 
of this criterion was not assessed in our study, since the 
included lesions were intentionally selected to exhibit mini-
mal scaling, allowing the best possible visualization of the 
underlying vessels.
Introduction
The induction of biologic agents targeting immunologic alter-
ations of psoriasis significantly changed the management of 
the disease. With gathering evidence and experience on their 
safety and efficacy, these agents acquired an important role in 
the management of psoriatic patients, and their use expanded 
worldwide [1]. The assessment of response to treatment with 
biologics is mainly based on the calculation of the PASI score, 
which is almost universally used in studies and clinical trials 
[2]. In daily practice, the application of PASI score is restricted 
by its complexity, and the routine evaluation of treatment is 
typically based on the physician’s global assessment and the 
patient’s perspective, which is typically quantified with the 
DLQI form [2,3].
Dermoscopy represents an easily applicable clinical diag-
nostic method of well-documented value for the diagnosis 
of skin tumors [4]. In addition, dermoscopy has been shown 
to be a valuable tool for monitoring response of skin cancer 
to topical treatment, especially after the application of non-
surgical modalities [5]. This is because it allows the visualiza-
tion of alterations occurring in sub-macroscopical structures 
as a result of the applied treatment.
More recently, the application of dermoscopy expanded 
also to the field of inflammatory and infectious skin diseases 
[6-9]. There is mounting evidence that dermoscopy enhances 
the differential diagnosis between psoriasis and other inflam-
matory dermatoses, such as dermatitis, lichen planus and 
pityriasis rosea [6]. Furthermore, it has been assumed that 
dermoscopy might also be useful for monitoring the response 
of psoriasis to systemic drugs by providing early signs of 
response to treatment and by revealing residual disease or 
recurrence before it becomes clinically evident [8]. Undoubt-
edly, such beneficial results of dermoscopy would be clinically 
relevant, providing clinicians early information on disease 
activity, thereby helping them to optimize patient treatment 
management. However, this hypothesis has not been tested 
up to date.
The aim of this study was to investigate whether dermo-
scopic criteria observed in psoriatic lesions of patients under 
treatment with biologics could improve the assessment of the 
response to the applied treatment.
Methods
This was a prospective multicentric study conducted in three 
dermatology centers in Greece and Italy. Patients with severe 
psoriasis scheduled to receive a biologic agent were enrolled 
in the study. During the time period of the study, which was 
between September 2013 and June 2015, the four available 
biologic agents were adalimumab, etanercept, infliximab and 
ustekinumab. Involved clinicians were free to administer the 
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ulation comparisons. We used Spear-
man’s rho coefficient to flag significant 
correlations, which were subsequently 
quantified. Odds ratios (OR), 95% 
confidence intervals (CI), and P values 
were calculated using univariate logis-
tic regression with categorical coding. 
Alpha level was set at 0.05. Statistical 
analyses were performed using the IBM 
SPSS 23.0 package (IBM SPSS Statistics 
for Windows, Version 23.0, Armonk, 
NY, IBM Corp).
Statistical analysis
The patients’ sex, drug administered, 
lesion location, clinical response (no 
response, patial response or complete 
response), vessel distribution (regular, 
clustered, minimal or none) and the 
presence of the purpuric dots were 
the variables used. Absolute and rela-
tive frequencies for all variables were 
obtained. Non-parametric Pearson’s 
Chi Square test was used for cross-tab-
Figure 1. The difference between red dots and hemorrhagic dots. (a) The red dots (dotted 
vessels) of psoriasis before treatment. (b) Hemorrhagic dots in a psoriatic plaque under treat-
ment. (c) Red dots (squares) and hemorrhagic dots (circles) in psoriatic lesion under treat-
ment. [Copyright: ©2016 Lallas et al.]
Results
Overall, 92 individuals were enrolled 
at baseline. Of them, nine patients 
were lost at follow-up before complet-
ing the designed study period, while in 
eight patients the treatment was termi-
nated or changed because of adverse 
events. Of 75 finally included patients, 
34 were men (45.3%) and 41 women 
(54.7%). Mean age at baseline was 48.7 
years and did not differ significantly 
between genders. Of 75 target lesions, 
45 were located on the trunk (60.0%) 
and 30 on an extremity (40.0%). The 
administered drugs were adalimumab 
in 31 patients (41.3%), etanercept in 
20 patients (26.7%), infliximab in 11 
patients (14.7%) and ustekinumab in 
14 patients (17.3%).
No clinical response of the target 
lesion after one month of treatment 
was seen in 29 patients (38.7%), par-
tial response in 34 (45.3%) and com-
plete response in 12 patients (16%). 
After two months of treatment, the 
clinical response of the target lesion 
was assessed as absent in 16 patients 
(21.3%), partial in 31 patients (41.3%) 
and complete in 28 patients (37.3%). 
Finally, after six months of treatment, 
11 target lesions (14.7%) were assessed 
as not responding, 23 (30.7%) as having 
responded partially and 41 (54.7%) as 
having remitted completely. During the 
study, clinical recurrence was detected 
in 8 target lesions, meaning that these 
plaques were assessed as completely 
responding at a time point and partially 
or not responding at a later point.
At baseline visit, all included lesions 
dermoscopically exhibited red dots dis-
tributed regularly and densely all over 
the surface of the lesion, while purpuric 
dots were present only in one case. The 
results of the dermoscopic analysis at all 
follow up visits are shown in Table 1.
Results of the clinical and dermo-
scopic analysis at follow-up visits
Overall, there was a significant cor-
relation between clinical response and 
vessel distribution at each time point 
Figure 2. Examples of hemorrhagic dots. Their presence was strongly associated with a sub-
sequent clinical response to treatment. [Copyright: ©2016 Lallas et al.]
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dots at one time point and the clinical 
response at following time points of 
the study. In particular, we investigated 
the association between the presence 
of hemorrhagic dots at T1 and clinical 
response at T2 and T3, as well as the 
presence of hemorrhagic dots at T2 and 
the clinical response at T3.
After multivariate regression, the 
presence of hemorrhagic dots at T1 
posed 20-fold higher odds for partial 
response at T2 (OR=20.125, 95%CI: 
3.73-108.62, p<0.001) and 10-fold 
higher odds for complete response at 
T2 (OR=20.818, 95%CI: 2.05-57.15, 
p=0.005). In addition, lesions displaying 
hemorrhagic dots at T1 had an 8-fold 
(Figure 3). In detail, at all time points, 
a regular vessel distribution correlated 
with no response, a clustered distri-
bution with partial response, and the 
dermoscopic absence of vessels with 
complete response (T1: Spearman’s rho 
= -0.755, p<0.001; T2: rho=-0.677, 
p<0.001; T3: rho=-0.746, p<0.001).
Notably, 7 of 8 recurring lesions 
lacked a clinical-dermoscopic corre-
lation, because at the visit when they 
were clinically assessed as completely 
responding, they displayed minimal or 
clustered vessels dermoscopically.
Several analyses were performed 
to investigate the possible correlation 
between the presence of hemorrhagic 
Table 1. Results of the clinical and dermoscopic analysis at follow-up visits. [Copyright: 
©2016 Lallas et al.]
Dermoscopic criteria T1 (1 month) T2 (2 months) T3 (6 months)
Clinical response
 None
 Partial
 Complete
29 (38.7%)
34 (45.3%)
12 (16.0%)
16 (21.3%)
31 (41.3%)
28 (37.3%)
11 (14.7%)
23 (30.7%)
41 (54.7%)
Vessel distribution
 Regular
 Clustered
 Minimal
 None
31 (41.3%)
21 (28.0%)
15 (20.0%)
 8 (10.7%)
14 (18.7%)
19 (25.3%)
22 (29.3%)
20 (26.7%)
16 (21.3%)
14 (18.7%)
17 (22.7%)
28 (37.3%)
Purpuric dots 42 (56.0%) 31 (41.3%)  5 (6.7%)
Figure 3. At follow-up visits: (a) Dermoscopy of lesions clinically assessed as non-responding 
usually revealed a regular distribution of red dots. (b) A strong association was found be-
tween partial clinical response and a clustered vessel arrangement in dermoscopy. (c) A com-
plete clinical response was typically associated with a complete dermoscopic disappearance 
of vessels. [Copyright: ©2016 Lallas et al.]
higher probability for partial response 
at T3 (OR=8.437, 95%CI: 1.46-
48.85, p=0.017) and a 7-fold higher 
probability for complete response at 
T3 (OR=7.031, 95%CI: 1.34-36.82, 
p=0.021). Similarly, the presence of 
hemorrhagic dots at T2 was associ-
ated with a 11-fold higher probability 
for partial response at T3 (OR=10.91, 
95%CI: 1.19-99.68, p=0.034) and an 
8-fold higher probability for complete 
response at T3 (OR=8.636, 95%CI: 
1.01-73.79, p=0.021).
Notably, due to limited sample size, 
we were not able to adequately quantify 
the latter associations within each sub-
group of the four different drugs used. 
However, our descriptive results indicate 
that the predictive effect of hemorrhagic 
dots is not influenced by the adminis-
tered drug.
Finally, no other parameter, including 
age, sex and location of the lesion, was 
significantly correlated with re sponse at 
any time.
Discussion
Our results suggest that dermoscopy is 
useful in assessing and predicting treat-
ment response of psoriatic lesions to 
treatment with biologic agents. Spe-
cifically, the appearance of dermoscopic 
hemorrhagic dots represents an early 
predictor of clinical response to treat-
ment, while reappearance of dotted ves-
sels correlate with disease recurrence 
(Figures 4 and 5).
Undoubtedly, the assessment of 
disease’s response to treatment with 
biologic agents is based on the overall 
clinical examination. PASI score is the 
most commonly used tool for evaluat-
ing the disease severity and is almost 
universally used in studies and clinical 
trials [2]. However, PASI reduction has 
been shown to correlate poorly with the 
patient’s perception of treatment success 
[3]. Effectively, in clinical practice, the 
evaluation of treatments and the deci-
sion for subsequent therapeutic plans 
are based on a more global assessment 
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the previous failure of a biologic agent 
was shown to represent a negative pre-
dictor of survival of the subsequent drug 
[3]. Considering the latter, as well as 
the limited range of biologic agents for 
severe psoriasis, developing and adopt-
ing strategies aiming to prolong the sur-
vival of these agents is considered one of 
the major goals for the near future. In 
this context, any reliable additional and 
early information on the disease activity 
and its response to treatment would be 
by the physicians in conjunction with 
the patient’s perspectives and satisfac-
tion.
The high efficacy of biologic agents 
significantly altered the perspectives of 
both clinicians and patients for thera-
peutic success. However, all biologic 
agents have been associated with treat-
ment discontinuation in a considerable 
proportion of patients, with ineffective-
ness and loss of efficacy being the com-
monest reasons [3,13-16]. Furthermore, 
very useful for clinicians in optimizing 
therapeutic plans.
The dermoscopic pattern of psori-
asis has been adequately investigated, 
with regularly distributed dotted vessels 
known to represent the dermoscopic hall-
mark of the disease [6,10]. Specifically, it 
has been demonstrated that all psoriatic 
plaques regularly display distributed dot-
ted vessels, even when located on specific 
body sites such as the scalp, palms/soles 
and folds [10]. The universal presence of 
dotted vessels in psoriatic plaques has 
led to the suggestion that the absence of 
such a vascular pattern should exclude 
the diagnosis of psoriasis [9]. In addi-
tion, dermoscopy has been assessed as an 
accurate method to differentiate psoriasis 
from the erythematosquamous skin dis-
eases, such as dermatitis, lichen planus 
and pityriasis rosea [6].
Although the latter data suggest 
that dermoscopy might be useful for 
recognizing clinically atypical psoria-
sis, this might not be clinically relevant 
for patients with moderate-to-severe 
disease, where the clinical diagnosis is 
usually straightforward, based on the 
typical morphology and distribution 
of skin lesions. However, our findings 
indicate that when these patients are 
treated with biologic agents, dermos-
copy might provide useful information 
on the response to treatment and the 
disease activity. In detail, the appearance 
of hemorrhagic dots was shown to rep-
resent an early predictor of subsequent 
clinical response at all time points of our 
study. This finding might help clinicians 
to predict a favorable response to treat-
ment even before clinical improvement 
appears or to expect a further improve-
ment of lesions partially responding. 
This might reduce the risk of falsely 
assessing the drug as inefficacious in 
patients where clinical response appears 
later than the average time period.
Furthermore, our findings provide 
an initial indication that dermoscopy 
might enable an early detection of 
disease recurrence, since all recurring 
lesions in our study were characterized 
Figure 4. (a) A psoriatic lesion at baseline (T0). (b) No clinical response is observed after one 
month of treatment (T1). However, dermoscopy reveals numerous hemorrhagic dots. (c) One 
month later (T2), the lesion has clinically and dermoscopically remitted completely.
Figure 5. (a) A psoriatic lesion at baseline (T0). (b) After two months of treatment (T2), the 
lesion was clinically assessed as completely remitted. However, dermoscopy did not reveal the 
expected complete disappearance of vessels. (c) After four months (T3), the lesion had also 
recurred clinically. [Copyright: ©2016 Lallas et al.]
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criteria for the diagnosis of psoriasis, dermatitis, lichen planus and 
pityriasis rosea. Br J Dermatol 2012;166(6):1198-1205. PMID: 
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bjd.12422.
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by a lack of clinical-dermoscopic correlation. Specifically, 
although clinically assessed as completely responding, they 
dermoscopically displayed dotted vessels (minimal or in 
clusters). Indeed, at the subsequent visit they recurred also 
clinically. An early recognition of disease recurrence might 
be particularly relevant, since strategies to reinforce the drug 
efficacy do exist.
In conclusion, our results provide an initial indication 
that dermoscopy might be useful for evaluating the response 
of psoriatic patients to biologic agents. Hemorrhagic dots 
represent an early predictor of subsequent clinical response, 
while the persistence or reappearance of dotted vessels might 
predict a subsequent clinical recurrence. This information 
might improve the assessment of disease activity and serve the 
goal of prolonging the survival of biologic agents.
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